コンテンツへスキップ
Merck
  • Histamine in the locus coeruleus promotes descending noradrenergic inhibition of neuropathic hypersensitivity.

Histamine in the locus coeruleus promotes descending noradrenergic inhibition of neuropathic hypersensitivity.

Pharmacological research (2014-10-12)
Hong Wei, Cong-Yu Jin, Hanna Viisanen, Hao-Jun You, Antti Pertovaara
要旨

Among brain structures receiving efferent projections from the histaminergic tuberomammillary nucleus is the pontine locus coeruleus (LC) involved in descending noradrenergic control of pain. Here we studied whether histamine in the LC is involved in descending regulation of neuropathic hypersensitivity. Peripheral neuropathy was induced by unilateral spinal nerve ligation in the rat with a chronic intracerebral and intrathecal catheter for drug administrations. Mechanical hypersensitivity in the injured limb was assessed by monofilaments. Heat nociception was assessed by determining radiant heat-induced paw flick. Histamine in the LC produced a dose-related (1-10μg) mechanical antihypersensitivity effect (maximum effect at 15min and duration of effect 30min), without influence on heat nociception. Pretreatment of LC with zolantidine (histamine H2 receptor antagonist), but not with pyrilamine (histamine H1 receptor antagonist), and spinal administration of atipamezole (an α2-adrenoceptor antagonist), prazosine (an α1-adrenoceptor antagonist) or bicuculline (a GABAA receptor antagonist) attenuated the antihypersensitivity effect of histamine. The histamine-induced antihypersensitivity effect was also reduced by pretreatment of LC with fadolmidine, an α2-adrenoceptor agonist inducing autoinhibition of noradrenergic cell bodies. Zolantidine or pyrilamine alone in the LC failed to influence pain behavior, while A-960656 (histamine H3 receptor antagonist) suppressed hypersensitivity. A plausible explanation for these findings is that histamine, due to excitatory action mediated by the histamine H2 receptor on noradrenergic cell bodies, promotes descending spinal α1/2-adrenoceptor-mediated inhibition of neuropathic hypersensitivity. Blocking the autoinhibitory histamine H3 receptor on histaminergic nerve terminals in the LC facilitates release of histamine and thereby, increases descending noradrenergic pain inhibition.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リドカイン, powder
Sigma-Aldrich
L-リシン 一塩酸塩, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 98.5-101.0%
Sigma-Aldrich
ヒスタミン 二塩酸塩, ≥99% (TLC), powder
Sigma-Aldrich
ヒスタミン, ≥97.0%
USP
リドカイン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
ヒスタミン 二塩酸塩, ≥99.0% (AT)
Sigma-Aldrich
シメチジン
Sigma-Aldrich
リドカイン, analytical standard
Sigma-Aldrich
L-リシン 一塩酸塩, reagent grade, ≥98% (HPLC)
Sigma-Aldrich
ピリラミン マレイン酸塩
Supelco
リドカイン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
ヒスタミン, analytical standard
USP
シメチジン, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
(+)-ビククリン, ≥97.0% (TLC)
Supelco
L-リシン 一塩酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-リシン 一塩酸塩, BioUltra, ≥99.5% (AT)
リシン 塩酸塩, European Pharmacopoeia (EP) Reference Standard
Supelco
L-リシン 一塩酸塩, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Supelco
シメチジン, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
ピリラミン マレイン酸塩, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Lysine hydrochloride solution, 100 mM amino acid in 0.1 M HCl, analytical standard
リドカイン, European Pharmacopoeia (EP) Reference Standard
ヒスタミン 二塩酸塩, European Pharmacopoeia (EP) Reference Standard
ピリラミン マレイン酸塩, European Pharmacopoeia (EP) Reference Standard
シメチジン, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
L-リシン 一塩酸塩, SAJ special grade, ≥99.0%
シメチジン, European Pharmacopoeia (EP) Reference Standard
システム適合性用シメチジン, European Pharmacopoeia (EP) Reference Standard